CD274 and neoplasm: Recently, there has been an increasing amount of evidence of sustained tumor regression in patients with melanoma and non-small-cell lung cancer after treatment with immunotherapies targeting immune checkpoints such as programmed cell death-1 ligand 1 (PD-L1) [24,25].